Masugi F, Ogihara T, Hasegawa T, Kumahara Y
Clin Exp Hypertens A. 1987;9(7):1233-42. doi: 10.3109/10641968709160046.
Circulating inhibitor of Na+,K+-ATPase and ouabain-like immunoreactivity were studied in patients with essential hypertension. In the plasma of patients, two types of Na+,K+-ATPase inhibitors (ouabain-like and non-ouabain-like inhibitors) and ouabain-like immunoreactivity were detected. Ouabain-like inhibitor was clearly detected at a low KCl concentration (0.1 mM) in the assay buffer, and non-ouabain-like inhibitor was detected at a high KCl concentration (10 mM). The plasma level of ouabain-like inhibitor correlated significantly with that of ouabain-like immunoreactivity (p less than 0.001) and with a mean blood pressure (p less than 0.01). The plasma level of non-ouabain-like inhibitor was not correlated with the levels of either ouabain-like immunoreactivity or mean blood pressure. The level of plasma ouabain-like inhibitor did not correlate with that of plasma non-ouabain like inhibitor. Both ouabain-like inhibitor and ouabain-like immunoreactivity in the plasma of patients with essential hypertension were significantly higher than those in normotensive subjects, but the plasma level of non-ouabain-like inhibitor in patients with essential hypertension was not higher than that in normotensive subjects. These results suggest that the plasma from patients with essential hypertension contains ouabain-like factor(s) which is important to maintain the high blood pressure.
对原发性高血压患者的循环性钠钾ATP酶抑制剂和哇巴因样免疫反应性进行了研究。在患者血浆中，检测到两种类型的钠钾ATP酶抑制剂（哇巴因样抑制剂和非哇巴因样抑制剂）以及哇巴因样免疫反应性。在测定缓冲液中低氯化钾浓度（0.1 mM）时能清晰检测到哇巴因样抑制剂，在高氯化钾浓度（10 mM）时能检测到非哇巴因样抑制剂。哇巴因样抑制剂的血浆水平与哇巴因样免疫反应性显著相关（p<0.001），且与平均血压相关（p<0.01）。非哇巴因样抑制剂的血浆水平与哇巴因样免疫反应性水平或平均血压均无相关性。血浆中哇巴因样抑制剂水平与非哇巴因样抑制剂水平无相关性。原发性高血压患者血浆中的哇巴因样抑制剂和哇巴因样免疫反应性均显著高于血压正常者，但原发性高血压患者血浆中非哇巴因样抑制剂水平并不高于血压正常者。这些结果表明，原发性高血压患者血浆中含有对维持高血压很重要的哇巴因样因子。
